{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-194625","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2023-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.756486+00:00","generated_at":"2026-06-13T02:22:32.651185+00:00","sec_items":["1.01","2.03","3.02","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Verrica closes $125M debt financing from OrbiMed; $50M funded, $75M tranched on revenue milestones","bullets":["$50M borrowed at closing; up to $75M additional available in five tranches subject to YCANTH revenue thresholds.","Five-year term loan matures July 2028; interest rate is one-month SOFR plus 8% (floor 4%).","OrbiMed receives warrant for 518,551 shares at $6.0264 per share (10-year term).","Proceeds support commercialization of YCANTH, FDA-approved July 21, 2023 for molluscum contagiosum.","Cash runway extended into Q1 2025; company believes no additional equity financing needed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-194625","json":"https://secwatch.observer/filing/0001193125-23-194625.json","markdown":"https://secwatch.observer/filing/0001193125-23-194625.md","text":"https://secwatch.observer/filing/0001193125-23-194625.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312523194625/0001193125-23-194625-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312523194625/d519666d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T02:22:32.651185+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"036e946739b9f9b3954aecd3d48659c21efdc226","claim":"Verrica Pharmaceuticals Inc. incurred credit facility of up to $125 million with OrbiMed Royalty & Credit Opportunities IV, LP at the higher of (x) the SOFR rate and (y) 4.00% plus 8.00% maturing July 26, 2028.","evidence_excerpt":"The Credit Agreement provides for a five-year senior secured credit facility in an aggregate principal amount of up to $125 million","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312523194625/0001193125-23-194625-index.htm","confidence":0.95,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"up to $125 million"},{"label":"Counterparty","value":"OrbiMed Royalty & Credit Opportunities IV, LP"},{"label":"Rate","value":"the higher of (x) the SOFR rate and (y) 4.00% plus 8.00%"},{"label":"Maturity","value":"July 26, 2028"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"3dc0d171b347dbab8704702816634b4570ac4b0d","claim":"Verrica Pharmaceuticals Inc. entered into Credit Agreement with OrbiMed Royalty & Credit Opportunities IV, LP valued at up to $125 million (effective 2023-07-26).","evidence_excerpt":"On July 26, 2023 (the “ Closing Date ”), Verrica Pharmaceuticals Inc., a Delaware corporation (the “ Company ”) entered into a Credit Agreement (the “ Credit Agreement ”), by and between the Company, as borrower, and OrbiMed Royalty & Credit Opportunities IV, LP, a Delaware limited partnership (the “ Initial Lender ”), as a lender, and each other lender that may from time to time become a party thereto (each, including the Initial Lender, and together with their affiliates, successors, transferees and assignees, the “ Lenders ”), and OrbiMed Royalty & Credit Opportunities IV, LP, as administrative agent for the Lenders (in such capacity, the “ Administrative Agent ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312523194625/0001193125-23-194625-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"OrbiMed Royalty & Credit Opportunities IV, LP"},{"label":"Value","value":"up to $125 million"},{"label":"Effective","value":"2023-07-26"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}